Peer-reviewedCC BY-NC-ND 4.0Scientific Reports
An interpretable machine-learning signature predicts early triple-negative breast cancer recurrence but adds no prognostic value beyond clinicopathological factors in external validation
Related
- Interpretable Machine Learning Prognostic Model Integrating Inflammatory-Nutritional Biomarkers for Post-Prostatectomy Biochemical Recurrence: Development, Internal Validation, and Translational Target Exploration.
- A Pathological Image-Based Pathomics Signature Combined with Clinicopathological Features for Predicting Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma: A Development and External Validation Study
- FMOD marks a low-malignancy epithelial state in prostate cancer: an ECM-related prognostic signature with single-cell and functional validation.
- Development and validation of an interpretable clinical-radiomics model for predicting 3-year postoperative recurrence in clinical stage I lung adenocarcinoma: a multicentre study.
- Development and validation of a prognostic prediction model for elderly patients with sepsis-associated acute kidney injury based on interpretable machine learning
BibTeX
@article{nan2026interpretable,
title = {{An interpretable machine-learning signature predicts early triple-negative breast cancer recurrence but adds no prognostic value beyond clinicopathological factors in external validation}},
author = {Haocheng Nan and Rong Di and Xiaorong Kou and Gang Ma},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-73601-9},
url = {https://www.nature.com/articles/s41598-026-73601-9},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - An interpretable machine-learning signature predicts early triple-negative breast cancer recurrence but adds no prognostic value beyond clinicopathological factors in external validation
AU - Haocheng Nan
AU - Rong Di
AU - Xiaorong Kou
AU - Gang Ma
PY - 2026
DA - 2026/10/12
JO - Scientific Reports
DO - 10.1038/s41598-026-73601-9
UR - https://www.nature.com/articles/s41598-026-73601-9
SN - 2045-2322
ER -